Teva's future in biosimilars shady as Lonza ends expensive JV
This article was originally published in Scrip
Executive Summary
Teva Pharmaceuticals and Lonza have hit the end of the road with their biologics joint venture, with Lonza citing costs as a main factor. The discontinuation leaves a huge question mark hanging over Teva's future plans for its biosimilars program, with some pundits wondering whether they might exit the scene completely.